Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma of Lung
Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
Biliary Tract Neoplasms
3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.
Brain Neoplasms
Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours.
Brain Neoplasms
[Epigenetic analyses of brain tumor stem cells]
Breast Neoplasms
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Breast Neoplasms
AMPK lifts the PRC2-implemented gene repression.
Breast Neoplasms
EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.
Breast Neoplasms
EZH2 inhibition sensitizes tamoxifen?resistant breast cancer cells through cell cycle regulation.
Breast Neoplasms
Gene set-based module discovery in the breast cancer transcriptome.
Breast Neoplasms
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Breast Neoplasms
MiR-101-3p and Syn-Cal14.1a Synergy in Suppressing EZH2-Induced Progression of Breast Cancer.
Carcinogenesis
An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting.
Carcinogenesis
AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Carcinogenesis
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Carcinogenesis
Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells.
Carcinogenesis
EZH2 inhibition sensitizes tamoxifen?resistant breast cancer cells through cell cycle regulation.
Carcinogenesis
EZH2 is a potential prognostic predictor of glioma.
Carcinogenesis
EZH2 promotes gastric cancer cells proliferation by repressing p21 expression.
Carcinogenesis
EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.
Carcinogenesis
HIFI-? activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
Carcinogenesis
Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Carcinogenesis
Long non-coding RNA functions in lung cancer.
Carcinogenesis
microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human glioma.
Carcinogenesis
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Carcinogenesis
Overexpression of suppressor of zest 12 is associated with cervical node metastasis and unfavorable prognosis in tongue squamous cell carcinoma.
Carcinogenesis
Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-wild-type Diffuse Astrocytic Gliomas.
Carcinogenesis
SUZ12 depletion suppresses the proliferation of gastric cancer cells.
Carcinogenesis
SUZ12 is a novel putative oncogene promoting tumorigenesis in head and neck squamous cell carcinoma.
Carcinogenesis
The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Carcinogenesis
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Carcinogenesis
Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Carcinogenesis
Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Carcinoma
Altered Histone Mark Deposition and DNA Methylation at Homeobox Genes in Human Oral Squamous Cell Carcinoma Cells.
Carcinoma
Epigenetic dysregulation of key developmental genes in radiation-induced rat mammary carcinomas.
Carcinoma
Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
Carcinoma
High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Carcinoma
Impact of human MLL/COMPASS and polycomb complexes on the DNA methylome.
Carcinoma
Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.
Carcinoma
P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.
Carcinoma
Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Carcinoma
[DZNep raises miR-200c expression to delay the invasion and migration of MGC-803 gastric carcinoma cells].
Carcinoma, Hepatocellular
Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Carcinoma, Hepatocellular
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Carcinoma, Hepatocellular
The Down-Regulation of SUZ12 Accelerates the Migration and Invasion of Liver Cancer Cells via Activating ERK1/2 Pathway.
Carcinoma, Hepatocellular
Tumor Suppressive Function of p21-activated Kinase 6 in Hepatocellular Carcinoma.
Carcinoma, Non-Small-Cell Lung
Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.
Carcinoma, Non-Small-Cell Lung
P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.
Carcinoma, Renal Cell
High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Carcinoma, Renal Cell
Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Altered Histone Mark Deposition and DNA Methylation at Homeobox Genes in Human Oral Squamous Cell Carcinoma Cells.
Chagas Disease
Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
Cholangiocarcinoma
Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Colonic Neoplasms
Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells.
Colorectal Neoplasms
Deregulated expression of microRNA-200b/c and SUZ12, a Polycomb repressive complex 2 subunit, in chemoresistant colorectal cancer cells.
Colorectal Neoplasms
EZH2 inhibition promotes methyl jasmonate-induced apoptosis of human colorectal cancer through the Wnt/?-catenin pathway.
Colorectal Neoplasms
Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Diabetic Cardiomyopathies
ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications.
Diabetic Nephropathies
ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications.
Diabetic Nephropathies
[EZH2 promotes development and progression of diabetic nephropathy].
Diabetic Retinopathy
Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells: potential relevance in diabetic retinopathy.
Encephalomyelitis
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Encephalomyelitis, Autoimmune, Experimental
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Endometriosis
Peritoneal Modulators of EZH2-miR-155 Cross-Talk in Endometriosis.
Ependymoma
EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Esophageal Squamous Cell Carcinoma
Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.
Glioblastoma
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Glioma
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Glioma
Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
Glioma
Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner.
Glioma
Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma.
Hematologic Neoplasms
Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
Hematologic Neoplasms
PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation.
Hepatitis B
EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes.
Huntington Disease
Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation.
Huntington Disease
Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations.
Infections
Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells.
Infections
Polycomb Repressive Complex 2 Silences Human Cytomegalovirus Transcription in Quiescent Infection Models.
Infections
Viral-encoded enzymes that target host chromatin functions.
Infections
Wedelolactone inhibits human cytomegalovirus replication by targeting distinct steps of the viral replication cycle.
Influenza, Human
Polycomb repressive complex 2 facilitates the nuclear export of the influenza viral genome through the interaction with M1.
Kidney Neoplasms
Epigenetic Marks Repressing Gluconeogenesis in Liver and Kidney Cancer.
Leukemia
Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Leukemia
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Leukemia
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Leukemia
Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Leukemia
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia.
Leukemia
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
Leukemia
The long non-coding RNA Fendrr links epigenetic control mechanisms to gene regulatory networks in mammalian embryogenesis.
Leukemia
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Leukemia, Myeloid, Acute
Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2.
Leukemia, Myeloid, Acute
Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.
Leukemia, Myeloid, Acute
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Leukemia, Promyelocytic, Acute
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia.
Liver Neoplasms
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer.
Lung Diseases
Ezh2 controls development of natural killer T cells, which cause spontaneous asthma-like pathology.
Lung Neoplasms
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Lung Neoplasms
Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer.
Lung Neoplasms
Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
Lung Neoplasms
EZH2 promotes progression of small cell lung cancer by suppressing the TGF-?-Smad-ASCL1 pathway.
Lung Neoplasms
Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer.
Lung Neoplasms
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
Lung Neoplasms
ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression.
Lung Neoplasms
Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.
Lymphatic Metastasis
linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.
Lymphoma
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma.
Lymphoma
Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.
Lymphoma
Polycomb repressive complex 2 (PRC2) suppresses E?-myc lymphoma.
Lymphoma, B-Cell
Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.
Lymphoma, Large B-Cell, Diffuse
Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.
Lymphoma, T-Cell
Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.
Lymphoma, T-Cell, Cutaneous
Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.
Medulloblastoma
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Melanoma
Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk.
Melanoma
EZH2 as a mediator of treatment resistance in melanoma.
Melanoma
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.
Mesothelioma
Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.
Mesothelioma, Malignant
Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
Multiple Myeloma
Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Multiple Myeloma
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Multiple Myeloma
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma.
Multiple Sclerosis
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Myelodysplastic Syndromes
EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms.
Myelodysplastic Syndromes
Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.
Neoplasm Metastasis
Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma.
Neoplasm Metastasis
linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.
Neoplasm Metastasis
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.
Neoplasm Metastasis
Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma.
Neoplasms
3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.
Neoplasms
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Neoplasms
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Neoplasms
Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Neoplasms
Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4.
Neoplasms
Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors.
Neoplasms
Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Neoplasms
AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Neoplasms
Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis.
Neoplasms
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Neoplasms
Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways.
Neoplasms
Characterization of the expression pattern of the PRC2 core subunit Suz12 during embryonic development of Xenopus laevis.
Neoplasms
Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types.
Neoplasms
Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
Neoplasms
Coordinated Regulation of Retinoic Acid Signaling Pathway by KDM5B and Polycomb Repressive Complex 2.
Neoplasms
Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
Neoplasms
Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer.
Neoplasms
Differential Expression of EZH2 and H3K27me3 in Oral Verrucous Carcinoma and Oral Verrucous Hyperplasia.
Neoplasms
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
Neoplasms
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
Neoplasms
DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma.
Neoplasms
DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment.
Neoplasms
Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells.
Neoplasms
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Neoplasms
EED inhibition suppresses cancers by modulating the immune response.
Neoplasms
EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms.
Neoplasms
ENHANCER OF ZESTE 2 (EZH2) IS UP-REGULATED IN MALIGNANT GLIOMAS AND IN GLIOMA STEM-LIKE CELLS.
Neoplasms
Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Neoplasms
Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis.
Neoplasms
Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Neoplasms
Enhancer of zeste homolog 2 blockade by RNA interference is implicated with inhibited proliferation, invasion and promoted apoptosis in endometrial carcinoma.
Neoplasms
Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.
Neoplasms
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
Neoplasms
Epigenetic Marks Repressing Gluconeogenesis in Liver and Kidney Cancer.
Neoplasms
Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.
Neoplasms
Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
Neoplasms
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Neoplasms
EZH2 enhances the invasive capability of renal cell carcinoma cells via activation of STAT3.
Neoplasms
EZH2 expression in invasive lobular carcinoma of the breast.
Neoplasms
EZH2 inhibition sensitizes tamoxifen?resistant breast cancer cells through cell cycle regulation.
Neoplasms
EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
Neoplasms
EZH2 is a potential prognostic predictor of glioma.
Neoplasms
EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Neoplasms
EZH2 overexpression in head and neck cancer is related to lymph node metastasis.
Neoplasms
EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer.
Neoplasms
EZH2 promotes gastric cancer cells proliferation by repressing p21 expression.
Neoplasms
EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
Neoplasms
EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.
Neoplasms
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Neoplasms
EZH2: novel therapeutic target for human cancer.
Neoplasms
First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor.
Neoplasms
Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines.
Neoplasms
G-tract RNA removes Polycomb repressive complex 2 from genes.
Neoplasms
Gene set-based module discovery in the breast cancer transcriptome.
Neoplasms
Genome-wide analysis of KAP1 binding suggests autoregulation of KRAB-ZNFs.
Neoplasms
H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.
Neoplasms
H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.
Neoplasms
Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells.
Neoplasms
Hhex Regulates Hematopoietic Stem Cell Self-Renewal and Stress Hematopoiesis via Repression of Cdkn2a.
Neoplasms
HIFI-? activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
Neoplasms
High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas.
Neoplasms
High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Neoplasms
Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Neoplasms
Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss.
Neoplasms
HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
Neoplasms
Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins.
Neoplasms
Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma.
Neoplasms
Identification of a Chemical Modulator of EZH2-mediated Silencing by Cell-based High-throughput Screening Assay.
Neoplasms
Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
Neoplasms
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
Neoplasms
Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Neoplasms
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Neoplasms
Integrated genomic analyses of de novo pathways underlying atypical meningiomas.
Neoplasms
JAK2 regulates mismatch repair protein-mediated epigenetic alterations in response to oxidative damage.
Neoplasms
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.
Neoplasms
Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma.
Neoplasms
Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.
Neoplasms
Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.
Neoplasms
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.
Neoplasms
Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.
Neoplasms
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.
Neoplasms
MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10.
Neoplasms
MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity.
Neoplasms
miR-367 as a therapeutic target in stem-like cells from embryonal central nervous system tumors.
Neoplasms
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Neoplasms
MUC1-C activates EZH2 expression and function in human cancer cells.
Neoplasms
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Neoplasms
Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.
Neoplasms
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
Neoplasms
Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
Neoplasms
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo.
Neoplasms
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
Neoplasms
Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-wild-type Diffuse Astrocytic Gliomas.
Neoplasms
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Neoplasms
Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.
Neoplasms
Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Neoplasms
Polycomb group proteins in cell cycle progression and cancer.
Neoplasms
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Neoplasms
Polycomb Repressive Complex 2 Enacts Wnt Signaling in Intestinal Homeostasis and Contributes to the Instigation of Stemness in Diseases Entailing Epithelial Hyperplasia or Neoplasia.
Neoplasms
Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neoplasms
Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner.
Neoplasms
Polycomb-like 3 promotes polycomb repressive complex 2 binding to CpG islands and embryonic stem cell self-renewal.
Neoplasms
Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
Neoplasms
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.
Neoplasms
PRC2 is dispensable for HOTAIR-mediated transcriptional repression.
Neoplasms
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
Neoplasms
PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs.
Neoplasms
PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep).
Neoplasms
Prognostic significance of EZH2 expression in patients with digestive cancers: a meta-analysis.
Neoplasms
Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.
Neoplasms
Promiscuous RNA binding by Polycomb repressive complex 2.
Neoplasms
Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines.
Neoplasms
Proteomic analyses identify a novel role for EZH2 in the initiation of cancer cell drug tolerance.
Neoplasms
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Neoplasms
Response to Comment on "Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2".
Neoplasms
Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells.
Neoplasms
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.
Neoplasms
Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
Neoplasms
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Neoplasms
SUMOylation of E2F1 Regulates Expression of EZH2.
Neoplasms
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Neoplasms
Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
Neoplasms
The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression.
Neoplasms
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma.
Neoplasms
The Multiple Facets of PRC2 Alterations in Cancers.
Neoplasms
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.
Neoplasms
The role of ASXL1 in hematopoiesis and myeloid malignancies.
Neoplasms
Towards understanding of PRC2 binding to RNA.
Neoplasms
TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep).
Neoplasms
Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
Neoplasms, Germ Cell and Embryonal
Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.
Neuralgia
EZH2 regulates spinal neuroinflammation in rats with neuropathic pain.
Neuroblastoma
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Neuroblastoma
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo.
Neuroblastoma
Origin and initiation mechanisms of neuroblastoma.
Neuroblastoma
Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma: FUNCTIONAL AND THERAPEUTIC IMPLICATIONS.
Neurodegenerative Diseases
Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations.
Neurofibrosarcoma
A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.
Neurofibrosarcoma
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Neurofibrosarcoma
H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.
Neurofibrosarcoma
H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.
Neurofibrosarcoma
Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss.
Neurofibrosarcoma
Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.
Neurofibrosarcoma
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.
Neurofibrosarcoma
Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.
Neurofibrosarcoma
Malignant Peripheral Nerve Sheath Tumors Show Decreased Global DNA Methylation.
Neurofibrosarcoma
Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
Neurofibrosarcoma
[Targeted therapy for malignant peripheral nerve sheath tumor: translational research and clinical application].
Osteosarcoma
Decreased long non-coding RNA lincFOXF1 indicates poor progression and promotes cell migration and metastasis in osteosarcoma.
Osteosarcoma
Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines.
Ovarian Neoplasms
EZH2-miRNA Positive Feedback Promotes Tumor Growth in Ovarian Cancer.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The role of polycomb repressive complex 2 in early T-cell precursor acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia.
Primary Myelofibrosis
Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis.
Prostatic Neoplasms
A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Prostatic Neoplasms
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Prostatic Neoplasms
HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
Prostatic Neoplasms
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Prostatic Neoplasms
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Prostatic Neoplasms
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Retinoblastoma
Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4.
Retinoblastoma
Dosage-sensitive function of retinoblastoma related and convergent epigenetic control are required during the Arabidopsis life cycle.
Retinoblastoma
Rbbp4 suppresses premature differentiation of embryonic stem cells.
Rett Syndrome
CAGE-defined promoter regions of the genes implicated in Rett Syndrome.
Sarcoma
CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.
Sarcoma
Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.
Sarcoma, Endometrial Stromal
CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.
Sarcoma, Endometrial Stromal
Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.
Seizures
Inhibition of EZH2 attenuates inhibitory synaptic transmission via the pro-inflammatory pathway in rats.
Skin Neoplasms
Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk.
Small Cell Lung Carcinoma
EZH2 promotes progression of small cell lung cancer by suppressing the TGF-?-Smad-ASCL1 pathway.
Squamous Cell Carcinoma of Head and Neck
Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma.
Stomach Neoplasms
Long noncoding RNA LINC00165-induced by STAT3 exerts oncogenic properties via interaction with Polycomb Repressive Complex 2 to promote EMT in gastric cancer.
Thyroid Neoplasms
Overexpression of Histone H3 Lysine 27 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer.
Urinary Bladder Neoplasms
EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway.
Urinary Bladder Neoplasms
linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.
Urinary Bladder Neoplasms
MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity.
[histone h3]-lysine27 n-trimethyltransferase deficiency
Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8(+) T Cell Terminal Differentiation and Loss of Multipotency.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2.1.1.356 [histone H3]-lysine27 N-trimethyltransferase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
